Bergapten alleviates osteoarthritis by regulating the ANP32A/ATM signaling pathway

Yi He1,2, Zeng Zisan3, Zhenhui Lu1,2, Li Zheng1,2 and Jinmin Zhao1,2,4,5

1 Guangxi Engineering Center in Biomedical Material for Tissue and Organ Regeneration, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
2 Guangxi Collaborative Innovation Center for Biomedicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
3 Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
4 Guangxi Key Laboratory of Regenerative Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
5 Department of Orthopaedics Trauma and Hand Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China

Keywords
ANP32A/ATM signal; bergapten; chondrocytes; IL-1β; osteoarthritis

Correspondence
Z. Lu and L. Zheng, Guangxi Engineering Center in Biomedical Material for Tissue and Organ Regeneration, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China
Fax: +86 07715350975
Tel: +860771540585 (ZL);
+86 0771538132 (LZ)
E-mails: zhenhulu1989@163.com (ZL);
zhengli224@163.com (LZ)

Yi He and Zisan Zeng contributed equally to this work

(Received 3 April 2019, revised 17 January 2019, accepted 29 April 2019)

doi:10.1002/2211-5463.12648

Osteoarthritis (OA) is a degenerative joint disease of the elderly which seriously affects the quality of life of patients and imposes a huge economic burden on families and society [1,2]. Clinically, chronic joint pain, stiffness, bone hypertrophy, bony friction and activity limitation are the most common pathogenesis of arthritis [3,4]. Drug therapy is among the most typical choices for treating OA [5]. First-line therapies include topical non-steroidal anti-inflammatory drugs and oral paracetamol, which have been demonstrated to relieve pain and the inflammatory processes of OA. However, they are accompanied by adverse events and unexpected risks, such as gastrointestinal and cardiovascular complications, limiting their clinical application [6,7].

Agents derived from plant extracts have attracted wide attention for treating the inflammatory diseases because...
of their multi-target effects and minimal side effects [8,9]. Bergapten (BG; 5-methoxypsoralen), a coumarin phytohormone that exists in multiple fruits such as figs and bergamot [10,11], has been reported to have potential in the treatment of skin diseases (such as psoriasis) [12,13]. The anti-inflammatory activities of BG, which has nearly no side effects, have been demonstrated both in vitro and in vivo. BG possibly modulated excessive cystic fibrosis lung inflammation by regulating the expression of the interleukin (IL)-8 gene in bronchial epithelial cells [13]. Bose et al. [14] also described that the production of pro-inflammatory cytokines, such as tumor necrosis factor α (TNF-α) and IL-6, could be significantly restrained by BG in lipopolysaccharide (LPS)-stimulated human peripheral blood mononuclear cells. Besides, BG has been proven to suppress inflammation by inhibiting the recruitment of neutrophils and macrophages in a tail-cutting-induced zebrafish injury site and reducing reactive oxygen species and nitric oxide generation [15]. Furthermore, Zheng et al. [16] found that BG inhibited osteoclastogenesis and bone resorption stimulated by LPS, which suggests BG could be taken as a possible treatment of inflammatory bone-destructive diseases. Thus, BG may be a potential candidate for OA therapy.

The acidic leucine-rich nuclear phosphoprotein-32A (ANP32A)/ataxia-telangiectasia mutated (ATM) axis plays an important role in the process of OA. ANP32A is one of the members of the ANP32 family [17], which participate in hormone receptor interactions, enzyme inhibition, cell adhesion, cell transport, gene expression regulation and apoptotic signaling pathways [18–20]. Single-nucleotide polymorphisms in the ANP32A gene were genotyped in two independent UK cohorts and a cohort from the Netherlands (a total of 2170 OA patients and 2849 normal controls). It was revealed that ANP32A was highly associated with OA in women [21]. Cornelis et al. [22] identified that ANP32A alleviated the progression of OA and protected cartilage from destruction due to the positive transcriptional regulation of ATM based on microarray profiling. Therefore, ANP32A/ATM may be a potential therapeutic target of OA.

In the present research, we investigated the effect of BG on the expression of pro-inflammatory cytokines in IL-1β-stimulated chondrocytes. We further studied whether BG suppresses the inflammatory factor through regulation of the ANP32A/ATM axis.

Materials and methods

Cell isolation and culture

All animal experimental processes were approved by the Animal Experimental Center of Guangxi Medical University (Nanning, China). Chondrocytes were isolated from the knee joints of 7-day-old Sprague–Dawley rats. Briefly, rats were sacrificed by an overdose of pentobarbital and the articular cartilage was collected from the knee joints. Subsequently, cartilages were cut into pieces ranging from 1 to 3 mm³ and digested with 2 mg mL⁻¹ collagenase II (Sigma, St. Louis, MO, USA) for 3 h at 37 °C. Then collected chondrocytes were suspended in complete culture medium supplemented with 10% fetal bovine serum (FBS; Gibco, Grand Island, NY, USA) and 1% penicillin–streptomycin (Solarbio, Beijing, China) and incubated at 37 °C in a humidified atmosphere containing 5% CO₂.

Bergapten treatment

Bergapten was purchased from Solarbio with purity ≥ 98% (HPLC). Second generation chondrocytes were digested and seeded into six-well plates, 24-well plates and 96-well plates at a density of 5 × 10⁴, 2 × 10⁴ and 5 × 10³ cells/well, respectively. The experiments were divided into three groups: (a) control group (chondrocytes treated with vehicle only); (b) IL-1β group (chondrocytes stimulated with 10 ng mL⁻¹); (c) IL-1β + BG group (chondrocytes cultured with 10 μM of BG for 1 h then stimulated with 10 ng mL⁻¹ IL-1β for 24 h).

Cytotoxicity assay

To assess the cytotoxic effect of BG on chondrocytes, a Cell Counting Kit-8 (CCK-8; Dojindo, Kumamoto, Japan) assay was performed. Chondrocytes seeded in 96-well plates were treated with BG at concentrations of 1, 5, 10, 50 and 100 μM for 72 h and then 10% of the volume of CCK-8 solution was added into each well. The absorbance was measured at 450 nm by a microplate reader (Thermo Fisher Scientific, Waltham, MA, USA) after 3 h of incubation.

Cell viability

The effect of BG on the viability of IL-1β-induced chondrocytes was assessed by fluorescein diacetate (FDA; Solarbio)/propidium iodide (PI; Sigma) staining. Cells were washed with PBS three times and incubated with 200 μL FDA/PI solution containing 0.5% FDA and 2% PI in the dark for 5 min at 37 °C. Images were obtained using a fluorescence inversion microscope (Leica, Wetzlar, Germany).

Cell morphology

Cells were rinsed three times with PBS and fixed with 95% ethanol for 30 min. They were then washed by PBS again and stained with hematoxylin and eosin (H&E; Solarbio). Finally, the images were observed by an inverted microscope (Leica).
**Safranin O staining**

Safranin O staining was used to assess the deposition of glycosaminoglycan (GAG). After washing three times with PBS, cells were fixed with 95% ethanol and stained with 0.1% safranin O (Solarbio) for 15 min. Images were captured through an inverted microscope.

**Cell proliferation and biochemical assay**

Chondrocytes were seeded in six-well plates and incubated with 10 µM BG for 1 h followed by stimulation with IL-1β for 24 h. Subsequently, the cells were collected by enzyme digestion and resuspended in 1 mL PBS containing 60 µg·mL⁻¹ proteinase K (Boster, Wuhan, China) and incubated at 60 °C for 12 h. After incubated with Hoechst 33258 (Boster) for 15 min, DNA content was calculated by measuring the absorbance at 525 nm of each sample. The absorbance of DNA was quantified with the BCA protein assay. Equal amounts of total protein (30 µg per lane) were fractionated on 10% SDS/PAGE gels and transferred onto PVDF membranes (Milli-pore, Billerica, MA, USA). After blocking in western blocking buffer (Beyotime, Beijing, China) for 2 h, the membranes were probed at 37 °C for 3 h with primary antibodies against MMP-13, IL-6, ATM and ANP32A (Boster; 1 : 200) at 4 °C overnight, followed by the secondary antibody—FITC anti-rabbit IgG (Boster; 1 : 200) in the dark for 30 min at room temperature. Finally, the nuclei were stained by 4',6-diamidino-2-phenylindole for 5 min and cells were viewed using a fluorescence microscope (Olympus, Tokyo, Japan).

**Quantitative real-time polymerase chain reaction analysis**

Quantitative real-time polymerase chain reaction (qRT-PCR) was conducted to quantify the gene expression levels of OA-specific markers including Il-1, Il-6, Cox-2, Tnf-α and Mmp-13 of chondrocytes. The primers used for qRT-PCR are shown in Table 1. The total RNA was extracted from each sample with a total RNA isolation kit (Megen-tec, Guangzhou, China). Then a reverse transcription kit (Fermentas Company, Waltham, MA, USA) was used to reverse transcribe RNA samples into cDNA. All qRT-PCR reactions were conducted by a LightCycler 96 system (Roche, Basel, Switzerland) under the conditions of 10 min at 95 °C to denature cDNA, then 40 cycles of 10 s at 95 °C, followed by 60 s at 60 °C that hybridized the primer with the target DNA. Experiments for each gene were assayed in sextuplicate. The relative gene expression levels were calculated by using the 2⁻ΔΔCt method to confirm the gene expression level relative to glyceraldehyde 3-phosphate dehydrogenase (GAPDH).

**Immunofluorescence analysis**

The expression levels of MMP-13, IL-6, ATM and ANP32A proteins in chondrocytes were quantified by immunofluorescence staining. After rinsing three times with PBS, chondrocytes were permeabilized by 0.1% Triton X-100. The cells were incubated with primary antibodies against MMP-13, IL-6, ATM and ANP32A (Boster; 1 : 200) at 4 °C overnight, followed by the secondary antibody—FITC anti-rabbit IgG (Boster; 1 : 200) in the dark for 30 min at room temperature. Finally, the nuclei were stained by 4',6-diamidino-2-phenylindole for 5 min and cells were viewed using a fluorescence microscope (Olympus, Tokyo, Japan).

**Western blot analysis**

Total protein was extracted using RIPA lysis buffer (Solarbio) supplemented with phenylmethylsulfonyl fluoride (Solarbio) for 60 min on ice. Protein concentration was quantified with the BCA protein assay. Equal amounts of protein (30 µg per lane) were fractionated on 5–10% SDS/PAGE gels and transferred onto PVDF membranes (Millipore, Billerica, MA, USA). After blocking in western blocking buffer (Beyotime, Beijing, China) for 2 h, the membranes were probed at 37 °C for 3 h with primary antibodies against MMP-13, IL-6, ATM and ANP32A antibodies (Boster; 1 : 500). Following washing with tris buffered saline tween (TBST) and incubation with secondary antibodies (Boster; 1 : 500) for 1 h, the signals were detected and visualized with an Odyssey Infrared Imaging System (LI-COR, St Charles, MO, USA).

**Statistical analyses**

All experiments in this study were performed independently six times (n = 6). Values are presented as mean ± SD, and SPSS STATISTICS 20.0 (IBM Corp., Armonk, NY, USA) was used for data analysis via one-way ANOVA and Tukey’s test. Differences were considered as statistically significant when P < 0.05.

---

**Table 1. Primers for RT-PCR**

| Gene     | Forward primer                         | Reverse primer                         |
|----------|----------------------------------------|----------------------------------------|
| Il-1     | 5'-GCACAGTTCCTCCAACTGGA-3'             | 5'-GGGAGACTGCCATTTCTCGAC-3'            |
| Il-6     | 5'-ACAAGTCCGAGAGGAGACT-3'             | 5'-ACAGTGCATCACTGCTGTTCC-3'           |
| Cox-2    | 5'-GATGACGAGAGCTGTTCCCA-3'            | 5'-CAGTTGAGTGGTGCCGGC-3'              |
| Tnf-α    | 5'-GACCAGCAGTCCGGTGTTCC-3'            | 5'-GAGGTCCCACTTCAGAGAA-3'             |
| Mmp-13   | 5'-CAATAGGGCATATCCCTCTAGAA-3'         | 5'-CCATGACCAAATCTCAGCTCCAC-3'         |
| Gapdh    | 5'-CTATATAAATTGGCGCCGCAG-3'           | 5'-AAAAACTCTGCGACTCC-3'               |

---

FEBS Open Bio 9 (2019) 1144–1152 © 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Results

Cytotoxicity of bergapten on chondrocytes

To evaluate the toxicity of BG on chondrocytes, cells were treated with different doses of BG and a CCK-8 assay was performed. The results revealed that BG at concentrations of 1–10 μM showed no cytotoxicity on chondrocytes (Fig. 1A). Thus, BG at a concentration of 10 μM was selected for the following experiments.

Effects of bergapten on proliferation and viability of chondrocytes

The effect of BG on the viability of chondrocytes that were stimulated by IL-1β was determined with a CCK-8 assay. Chondrocytes were cultured with or without BG for 1 h followed by stimulation with IL-1β (10 ng·mL⁻¹) for 24 h. As demonstrated in Fig. 1B, cell viability in the IL-1β group decreased to 79.16%. The cell viability of IL-1β-induced chondrocytes was increased to 108.87% with the addition of BG compared to the control group. FDA/PI staining also exhibited the same trends. More viable cells and fewer dead cells were exhibited in the BG-treated group compared to the IL-1β-only group (Fig. 1D).

The proliferation of chondrocyte was investigated by detecting DNA content. Cell proliferation was significantly decreased in the treatment of IL-1β only (P < 0.05), while a higher cell proliferation level was shown with BG pretreatment as evidenced by DNA content (Fig. 1C).

![Graph showing cell viability and DNA content](image1)

**Fig. 1.** Chondro-protective effects of BG on IL-1β-induced chondrocytes. (A) Cytotoxicity of BG at 0–100 μM was evaluated by CCK-8 assay after 72 h of incubation. (B) Cell viability of chondrocytes pretreated with culture medium only or BG followed by stimulation with IL-1β (10 ng·mL⁻¹) for 24 h was assessed by CCK-8 assay. (C) Quantification of DNA content for cell proliferation (mean ± SD, n = 6). (D) Cell viability by FDA/PI staining. (E) Cell morphology by hematoxylin–eosin staining (scale bars, 250 μm). Control group: chondrocytes treated with vehicle only; IL-1β group: chondrocytes stimulated with 10 ng·mL⁻¹ IL-1β; and IL-1β+BG group: chondrocytes cultured with 10 μM BG for 1 h then stimulated with 10 ng·mL⁻¹ IL-1β for 24 h. Mean ± SD, n = 6; ***P < 0.001 vs the control group; ##P < 0.01, ###P < 0.001 between the indicated experimental groups; data analysis by one-way ANOVA and Tukey’s test.
content (Fig. 1C). The results indicated that BG could effectively suppress the damage in cell proliferation induced by IL-1β.

Effects of bergapten on cell morphology

Morphological changes in chondrocytes after stimulation by IL-1β were investigated by H&E staining. As shown in Fig. 1E, normal chondrocytes were polygonal in shape. However, reductions of cytoplasm, cell volume and cell number were observed in the treatment with IL-1β. With the addition of BG, cells displayed polygonal morphology which was similar to the control. More cell colonies could be observed with the treatment by BG.

Effect of bergapten on IL-1β-induced GAG loss

The secretion of GAG in chondrocytes was determined by safranin-O staining (Fig. 2A). Chondrocytes treated with IL-1β showed loss of positive staining for GAG, while a large area of positive staining was exhibited in the presence of BG. The DMMB assay (Fig. 2B) showed that IL-1β significantly decreased the production of GAG by 21.8% compared to control. Pretreating with BG increased the GAG secretion by 86.1% in
comparison to the IL-1β-only group. This indicated that BG can restrain the IL-1β-induced GAG loss in chondrocytes.

Effects of bergapten on IL-1β-induced inflammatory responses in chondrocytes

To determine the effects of BG on IL-1β-induced inflammatory responses in chondrocytes, the gene expression levels of OA-specific markers Il-1, Il-6, Tnf-α, Cox-2 and Mmp-13 were examined using qRT-PCR (Fig. 2C–G). Chondrocytes stimulated with IL-1β were found to upregulate the mRNA expression of OA markers compared with control group. However, cells incubated with BG reversed the IL-1β-stimulated upregulation of Il-1, Il-6, Tnf-α, Cox-2 and Mmp-13 by 82.71%, 89.07%, 65.44%, 76.82% and 72.67%, respectively.

MMP-13 has been proved to be a key regulator during the progression of OA [23]. To explore the effect of BG on the IL-1β-induced upregulation of MMP-13 in chondrocytes, the expression of MMP-13 was analyzed by immunofluorescence staining (Fig. 3B,D) and western blot (Fig. 3E,F). As shown in Fig. 3D,F, an increased expression of MMP-13 was displayed in the treatment with IL-1β. However, the MMP-13 expression was obviously suppressed by adding BG. In addition, the impact of BG on inflammatory cytokine IL-6 was also examined by immunofluorescence staining (Fig. 3A,C) and western blot (Fig. 3E,F). BG attenuated the IL-6 expression which was upregulated by IL-1β.

Effect of bergapten on ANP32A/ATM axis upon IL-1β stimulation

The ANP32A/ATM axis has been reported to be involved in the development of OA. The effect of BG on ANP32A/ATM signal transduction that was stimulated by IL-1β was assessed using immunofluorescence staining and western blot analysis. Control group: chondrocytes treated with vehicle only; IL-1β group: chondrocytes stimulated with 10 ng/mL IL-1β; and IL-1β+BG group: chondrocytes cultured with 10 μM of BG for 1 h then stimulated with 10 ng/mL IL-1β for 24 h. Scale bars, 400 μm. Mean ± SD, n = 6; ***P < 0.001 vs the control group; *P < 0.05, **P < 0.01 between the indicated experimental groups; data analysis via one-way ANOVA and Tukey’s test.

Fig. 3. Immunofluorescence staining and western blot revealed the inhibitory effect of BG on the expression of IL-6 and MMP-13. (A–D) Immunostaining of IL-6 (A) and MMP-13 (B) and quantitative analysis of the fluorescence intensities (C,D) determined as fold-change vs the control group. (E,F) Protein levels of IL-6 and MMP-13 determined by western blot analysis. Control group: chondrocytes treated with vehicle only; IL-1β group: chondrocytes stimulated with 10 ng·mL⁻¹ IL-1β; and IL-1β+BG group: chondrocytes cultured with 10 μM of BG for 1 h then stimulated with 10 ng·mL⁻¹ IL-1β for 24 h. Scale bars, 400 μm. Mean ± SD, n = 6; ***P < 0.001 vs the control group; *P < 0.05, **P < 0.01 between the indicated experimental groups; data analysis via one-way ANOVA and Tukey’s test.
staining (Fig. 4A–D) and western blot (Fig. 4E,F). As demonstrated in Fig. 4A–F, in the treatment of IL-1β, the expression of ANP32A and ATM was significantly downregulated compared to control. However, a higher expression level was detected in the treatment with BG. The results indicated that BG could reverse the effect of IL-1β in stimulating chondrocytes via the ANP32A/ATM signal.

**Discussion**

This study investigated the effect of BG on OA. We found that BG could reverse IL-1β-induced inflammation and matrix loss of chondrocytes by regulation of the ANP32A/ATM pathway, contributing to delay in the progress of OA.

During the treatment process of OA, it is of significance to maintain the matrix metabolism of healthy cartilage and reduce cartilage degradation [24,25]. We discovered that BG constrained IL-1β-induced damage by accelerating the proliferation and maintaining the phenotype of chondrocytes. As evidenced by safranin O staining (Fig. 2A) and GAG content quantification (Fig. 2B), BG significantly promoted GAG secretion, which may be responsible for maintaining the balance of the extracellular matrix. MMP-13 has been confirmed to participate in the progression of OA since it targets and degrades collagen-II and proteoglycan, which are the main components of the extracellular matrix of cartilage [26]. In this study, we demonstrated that BG inhibited IL-1β-induced MMP-13 upregulation in chondrocytes (Fig. 3). In addition, BG could effectively limit the damage stimulated by IL-1β and promote cell proliferation, which was indicated by the DNA content (Fig. 1C) and FDA/PI staining (Fig. 1D). These results demonstrated that BG may be

![Fig. 4. Effect of BG on ANP32A/ATM axis upon IL-1β stimulation. (A–D) Immunostaining of ANP32A (A) and ATM (B) and relative expression (fold-change relative to control) (C, D). (E, F) Protein levels of ANP32A and ATM determined by western blot analysis. Control group: chondrocytes treated with vehicle only; IL-1β group: chondrocytes stimulated with 10 ng·mL⁻¹ IL-1β; and IL-1β+BG group: chondrocytes cultured with 10 μM of BG for 1 h then stimulated with 10 ng·mL⁻¹ IL-1β for 24 h. Scale bars, 400 μm. Mean ± SD, n = 6; *P < 0.05; ***P < 0.001 vs the control group; ###P < 0.001 between the indicated experimental groups; data analysis via one-way ANOVA and Tukey’s test.](image-url)
an effective regulator in proliferation and phenotype maintenance of chondrocytes in OA.

IL-1β can induce cellular inflammatory conditions and increase the production of pro-inflammatory cytokines including IL-6, TNF-α, COX-2 and MMP-13, which mediate the pathogenesis of OA [27]. In the previous study, BG has been reported to suppress the expression of pro-inflammatory cytokines induced by LPS [28]. Consistent with this finding, we also revealed that BG could reverse the expression of inflammatory cytokines and mediators induced by IL-1β in chondrocytes (Fig. 2).

The regulatory effect of ANP32A in OA has been confirmed [21]. A recent study also found that ATM is a positive transcriptional regulator in the expression of ANP32A [22]. Furthermore, ANP32A plays an important role in the progression of OA that largely depends on positively regulating the expression of ATM [6]. In our study, chondrocytes stimulated by IL-1β decreased the expression of ANP32A and ATM, but BG reversed the effect of IL-1β on inducing the lower expression of ANP32A and ATM (Fig. 4).

In summary, our study offers the new insight that BG can restrain the IL-1β-induced destruction of chondrocytes in vitro by inhibiting the expression of Il-1, Il-6, Tnf-α, Cox-2 and Mmp-13. Moreover, our results also revealed that the anti-inflammatory reaction of BG was by activating the ANP32A/ATM axis. These findings indicated that BG may be a promising candidate for the treatment of OA.

Acknowledgements

This study was financially supported by National Key Research and Development Program of China (2018YFC1105900, 2018YFC1105903), National Natural Science Fund of China (Grant No. 81860390), the Guangxi Science and Technology Base and Talent Special Project (Grant No. GuikeAD17129012), the Local Science and Technology Development Project leading by the Central Government (the three-D printing and digital medical platform, Grant No. GuikeZY18164004), the Guangxi Medical and Health Technology Development and Application Project (S201670) and the Basic Ability Enhancement Project for Young and Middle-Aged Teachers of Universities in Guangxi (2018KY0127).

Conflict of interest

The authors declare no conflict of interest.

Author contributions

JZ, LZ and ZL conceived and designed the project, LZ and YH acquired the data, ZL, ZZ and YH analysed and interpreted the data, and ZZ and YH wrote the paper.

References

1. Majeed MH, Sherazi SAA, Bacon D and Bajwa ZH (2018) Pharmacological treatment of pain in osteoarthritis: a descriptive review. Curr Rheumatol Rep 20, 88.
2. Tu C, He J, Wu B, Wang W and Li Z (2019) An extensive review regarding the adipokines in the pathogenesis and progression of osteoarthritis. Cytokine 113, 1–12.
3. Rodriguez-Merchan EC (2018) Topical therapies for knee osteoarthritis. Postgrad Med 130, 607–612.
4. Roman-Blas JA, Bizzi E, Largo R, Migliore A and Herrero-Beaumont G (2016) An update on the up and coming therapies to treat osteoarthritis, a multifaceted disease. Expert Opin Pharmacother 17, 1745–1756.
5. Li MH, Xiao R, Li JB and Zhu Q (2017) Regenerative approaches for cartilage repair in the treatment of osteoarthritis. Osteoarthritis Cartilage 25, 1577–1587.
6. Neto MF, Yokota H and Figueiredo ML (2018) Strategies for reducing inflammation and promoting bone repair in arthritis. Front Biosci 23, 318–347.
7. Martel-Pelletier J, Barr AJ, Cicuttini FM, Conaghan PG, Cooper C, Goldring MB, Goldring SR, Jones G, Teichtahl AJ and Pelletier JP (2016) Osteoarthritis. Nat Rev Dis Primers 2, 16072.
8. Hou PW, Fu PK, Hsu HC and Hsieh CL (2015) Traditional Chinese medicine in patients with osteoarthritis of the knee. J Tradit Complement Med 5, 182–196.
9. Mobasheri A (2012) Intersection of inflammation and herbal medicine in the treatment of osteoarthritis. Curr Rheumatol Rep 14, 604–616.
10. Ma J, Huang J, Hua S, Zhang Y, Zhang Y, Li T, Dong L, Gao Q and Fu X (2018) The ethnopharmacology, phytochemistry and pharmacology of Angelica biserrata – a review. J Ethnopharmacol 231, 152–169.
11. Hua-Bin L and Chen F (2004) Preparative isolation and purification of bergapten and imperatorin from the medicinal plant Cnidium monnieri using high-speed counter-current chromatography by stepwise increasing the flow-rate of the mobile phase. J Chromatogr A 1061, 51–54.
12. Calzavara-Pinton P, Zane C, Carlinio A and De Panfilis G (1997) Bath-5-methoxypsoralen-UVA therapy for psoriasis. J Am Acad Dermatol 36, 945–949.
13 Calzavara-Pinton P, Ortel B, Carlino A, Honigsmann H and De Panfilis G (1992) A reappraisal of the use of 5-methoxypsoralen in the therapy of psoriasis. Exp Dermatol 1, 46–51.

14 Bose SK, Dewanjee S, Sahu R and Dey SP (2011) Effect of bergapten from Heracleum nepalense root on production of proinflammatory cytokines. Nat Prod Res 25, 1444–1449.

15 Yang Y, Zheng K, Mei W, Wang Y, Yu C, Yu B, Deng S and Hu J (2018) Anti-inflammatory and proresolution activities of bergapten isolated from the roots of Ficus hirta in an in vivo zebrafish model. Biochem Biophys Res Commun 496, 763–769.

16 Zheng M, Ge Y, Li H, Yan M, Zhou J and Zhang Y (2014) Bergapten prevents lipopolysaccharide mediated osteoclast formation, bone resorption and osteoclast survival. Int Orthop 38, 627–634.

17 Matilla A and Radrizzani M (2005) The Anp32 family of proteins containing leucine-rich repeats. Cerebellum 4, 7–18.

18 Chai G, Feng Q, Wang ZH, Hu Y, Sun D, Li XG, Ke D, Li HL, Liu GP and Wang JZ (2017) Downregulating ANP32A rescues synapse and memory loss via chromatin remodeling in Alzheimer model. Mol Neurodegener 12, 34.

19 Reilly PT, Yu Y, Hamiche A and Wang L (2014) Cracking the ANP32A whips: important functions, unequal requirement, and hints at disease implications. BioEssays 36, 1062–1071.

20 Xie M, Ji Z, Bao Y, Zhu Y, Xu Y, Wang L, Gao S, Liu Z, Tian Z, Meng Q et al. (2018) PHAP1 promotes glioma cell proliferation by regulating the Akt/p27/stathmin pathway. J Cell Mol Med 22, 3595–3604.

21 Valdes AM, Lories RJ, van Meurs JB, Kerkhof H, Doherty S, Hofman A, Hart DJ, Zhang F, Luyten FP, Uitterlinden AG et al. (2009) Variation at the ANP32A gene is associated with risk of hip osteoarthritis in women. Arthritis Rheum 60, 2045–2054.

22 Cornelis FMF, Montegagudo S, Guns LKA, den Hollander W, Nelissen R, Storms L, Peeters T, Jonkers I and Meulenbelt I (2018) ANP32A regulates ATM expression and prevents oxidative stress in cartilage, brain, and bone. Sci Transl Med 10, 458.

23 Iliopoulos D, Malizos KN and Tsezou A (2007) Epigenetic regulation of leptin affects MMP-13 expression in osteoarthritic chondrocytes: possible molecular target for osteoarthritis therapeutic intervention. Ann Rheum Dis 66, 1616–1621.

24 Bertrand J, Cromme C, Umlauf D, Frank S and Pap T (2010) Molecular mechanisms of cartilage remodelling in osteoarthritis. Int J Biochem Cell Biol 42, 1594–1601.

25 Maldonado M and Nam J (2013) The role of changes in extracellular matrix of cartilage in the presence of inflammation on the pathology of osteoarthritis. Biomed Res Int 2013, 284873.

26 Aigner T, Söder S, Gebhard PM, McAlinden A and Haag J (2007) Mechanisms of disease: role of chondrocytes in the pathogenesis of osteoarthritis—structure, chaos and senescence. Nat Rev Nephrol 3, 391–399.

27 Fernandes JC, Martel-Pelletier J and Pelletier JP (2002) The role of cytokines in osteoarthritis pathophysiology. Biochimie 84, 237–246.

28 Yang JJ, Lee DU and Shin HM (2015) Anti-inflammatory and antioxidant effects of coumarins isolated from Foeniculum vulgare in lipopolysaccharide-stimulated macrophages and 12-O-tetradecanoylphorbol-13-acetate-stimulated mice. Immunopharmacol Immunotoxicol 37, 308–317.